Reata Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:RETA  
110.01
-0.71 (-0.64%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.97B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.22 Million
Adjusted EPS-$2.12
See more estimates
10-Day MA$109.24
50-Day MA$114.29
200-Day MA$116.38
See more pivots

Reata Pharmaceuticals Inc - Ordinary Shares - Class A Stock, NASDAQ:RETA

5320 Legacy Drive, Suite 150, Plano, Texas 75024
United States of America
Phone: +1.972.865.2219
Number of Employees: 273

Description

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.